Prof. Jin Zhang 张瑾
Chief Physician, Professor
Breast Surgery, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Surgical treatment of breast cancer, including breast-conserving surgery. Chemotherapy, endocrine therapy, and management of recurrence and metastasis.
Dr. Zhang holds an M.D., M.M., and Ph.D. from Tianjin Medical University and completed postdoctoral work there. Training includes roles at the University of Louisville and MD Anderson Cancer Center in the USA. Currently Professor and Director of the Third Department of Breast Oncology at Tianjin Medical University Cancer Institute & Hospital.
Professional roles
- Vice Chair, Breast Cancer Professional Committee, China Anti-Cancer Association
- Member, Oncology Branch, Chinese Medical Association
- Deputy Leader, Early Diagnosis and Treatment Group, Oncology Branch, Chinese Medical Association
- Vice Chair, Breast Cancer Expert Committee, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Zhang Jin). Papers usually list the name as Jin Zhang or Zhang J.
Selected publications
158 papers on PubMed matched by name and affiliation; 67 as first or senior author since 2016. Most recent first- or senior-author papers:
- Clin Cancer Res, 2026 (first author): Neoadjuvant Pertuzumab Biosimilar HLX11 Versus Reference Pertuzumab for Early-stage or Locally Advanced Breast Cancer: A phase 3 Equivalence Trial. PubMed 42714872
- Breast Cancer Res Treat, 2026 (senior author): Retraction Note: GGNBP2 suppresses triple-negative breast cancer aggressiveness through inhibition of IL-6/STAT3 signaling activation. PubMed 42579165
- Front Pharmacol, 2026 (senior author): Rapid relapse in triple-negative breast cancer: clinical patterns, platinum resistance, and implications for clonal evolution. PubMed 42499497
- World J Surg, 2026 (senior author): Dynamic Evolution of HER2 Expression Following Neoadjuvant Therapy and Its Association With Treatment Response and Prognosis in Breast Cancer: A Large-Scale Retrospective Study. PubMed 42202038
- Gland Surg, 2026 (senior author): Comparison of neoadjuvant TCbHP versus THP in HER2-positive breast cancer: a retrospective cohort study. PubMed 42445064
- Eur J Cancer, 2026 (senior author): Retraction notice to "Effects of the combination of RAD001 and docetaxel on breast cancer stem cells" [Eur J Cancer 48 (2012) 1581-1592]. PubMed 41982023
- Cancer Res Treat, 2026 (senior author): Distinct Evolutionary Dynamics of HER2-Ultralow Versus HER2-Null from Residual to Metastatic Disease in Non-pCR Breast Cancer. PubMed 42128020
- Cancer Inform, 2026 (first author): A Prognostic 9-Gene Signature Linked to Autophagy-Dependent Cell Death in Hepatocellular Carcinoma. PubMed 41836037
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion